Amicus Therapeutics Inc

Amicus Therapeutics — Q2 2025 Earnings Presentation

26 slides from Amicus Therapeutics's earnings presentation, Jul 31, 2025

  1. Slide 1: Q2 2025 Results Conference Call & Webcast

    AT T H E F O R E F R O N T O F THERAPIES FOR RARE DISEASES Q2 2025 Results Conference Call & Webcast July 31, 2025

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing approval of our products, commercialization plans, manufacturing

  3. Slide 3: A Rare Company

    A Rare Company A unique story in biotech with significant revenue growth and profitability First Two- 10-15% 50-65% First Oral Component Therapy Precision for Pompe Disease Medicine for Fabry Disease FY 2025 FY 2025 Galafold Revenue Pombiliti + Opfolda Growth1 Revenue Growth1 $155M Expanded Portfoli

  4. Slide 4: Galafold Continued Growth

    Galafold ® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 4

  5. Slide 5: 2025 Galafold Success (as of June 30, 2025)

    2025 Galafold Success (as of June 30, 2025) Only approved oral treatment in Fabry disease and standard of care for amenable patients A unique mechanism of action for Fabry patients with amenable variants $128.9M Q2 25 Galafold 69% +16% Revenue Share of Treated Q2 25 Reported Amenable Patients Sales

  6. Slide 6: Galafold Performance

    Galafold Performance Q2 2025 Galafold reported revenue of $128.9M (+12% growth at CER) +10-15%1  Quarterly patient starts remain strong: +13% growth $458M in Q2 YoY $388M Q4  The US contributed significantly to growth reaching >1,000 PRFs since launch $128M Q3  Global mix of naïve (~65%) and swit

  7. Slide 7: Fabry Market: Significant Remaining Unmet Need

    Fabry Market: Significant Remaining Unmet Need Research suggests there could be >100k people living with Fabry disease who remain undiagnosed U.S. 36% Undiagnosed (Est. >100,0001) Diagnosed Untreated (~6,0001) Treated Population (>12,0001) Europe 36% ROW Based on publicly reported sales of Fabry the

  8. Slide 8: Pombiliti + Opfolda

    Pombiliti® (cipaglucosidase alfa-atga) + ® Opfolda (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 8

  9. Slide 9: Pombiliti + Opfolda Performance

    Pombiliti + Opfolda Performance Q2 2025 Pombiliti + Opfolda reported revenue of $25.8M (+58% at CER) +50-65%1  Strong Q2 sales growth YoY – Highest demand quarter since launch – Increasing depth and breadth of prescribers $70.2M Q4 $22M  H2 2025 growth driven by: Q3 Q2 – Benefit of new patient sta

  10. Slide 10: Pombiliti + Opfolda Expansion

    Pombiliti + Opfolda Expansion Significant progress made towards expanding access to Pombiliti + Opfolda in 2025 Regulatory Reimbursement  First commercial patients in six new countries in H1 2025  Approved in Japan in June 2025  Pombiliti + Opfolda selected as preferred treatment  Approved in Au

  11. Slide 11: Pombiliti + Opfolda Body of Evidence

    Pombiliti + Opfolda Body of Evidence Growing number of abstracts, manuscripts, and case studies supporting Pombiliti + Opfolda differentiation Clinical Trials & Long-Term Data  Long-term Phase 1/2 open-label safety and efficacy study (ATB200-02)  104-week Phase 3 open-label extension study of effi

  12. Slide 12: Real World Evidence: Case Studies

    Real World Evidence: Case Studies Case studies support experience of patients switching from Nexviazyme to Pombiliti + Opfolda Nexviazyme to PomOp Switch Lumizyme to Nexviazyme to PomOp Switch Impacts on: Hex4, CK, MMT (Upper), FVC Impacts on: Hex4, CK, MMT (Lower), FVC, 6MWD 12 Presented at 2025 Am

  13. Slide 13: DMX-200

    DMX-200 Potential first-in-class investigational small molecule for the treatment of FSGS in the U.S. 13

  14. Slide 14: Focal Segmental Glomerulosclerosis (FSGS) is a rare disease leading to irreversible kidney damage

    Focal Segmental Pathogenic Feedback Glomerulosclerosis (FSGS) Loop in FSGS is a rare disease leading to DMX-200 irreversible kidney damage Existing blood pressure specifically blocks kidney medication targets inflammatory signaling angiotensin receptor blocker (ARB) lowers Kidney vessels have to wor

  15. Slide 15: DMX-200 Mechanism of Action

    DMX-200 Mechanism of Action DMX-200 works synergistically with ARBs to act on innate inflammatory signaling pathway in the kidney Kidney Damaged Kidney Kidney Cells and Cells Cells (FSGS) Monocytes DMX-200 + ARB AT1R Heteromer AT1R + CCR2 CCR2 Traditional  Blocks MCP-1–mediated signaling through An

  16. Slide 16: DMX-200 Clinical and Regulatory Progress

    DMX-200 Clinical and Regulatory Progress Dimerix has built a strong body of evidence and made significant clinical and regulatory progress Precision therapy to disrupt the pathogenic monocyte-driven inflammatory feedback MOA loop in the kidney of patients with FSGS Positive efficacy signals and well

  17. Slide 17: Corporate Outlook

    Corporate Outlook Delivering on our mission for patients and shareholders 17

  18. Slide 18: Q2 2025 Select Financial Results

    Q2 2025 Select Financial Results Q2 2025 revenue of $154.7M, up 18% at CER and non-GAAP net income of $1.9M Q2’25 H1’25 (in thousands, except per share data) Jun. 30, 2025 Jun. 30, 2024 Jun. 30, 2025 Jun. 30, 2024 Net product sales $ 154,688 $ 126,669 $ 279,937 $ 237,072 Cost of goods sold 15,217 11

  19. Slide 19: FY 2025 Financial Guidance Reiterated

    FY 2025 Financial Guidance Reiterated FY 2025 Financial Guidance1 Total Revenue Growth1 15% to 22% Galafold Revenue Growth1 10% to 15% FY 2025 Revenue Sensitivity Given the proportion of Amicus revenue ex-US Pombiliti + Opfolda Revenue Growth1 50% to 65% (~60% in 2024), a change in USD exchange rate

  20. Slide 20: 2025 Strategic Priorities

    2025 Strategic Priorities Deliver total revenue growth of 15-22% at CER1 Double-digit Galafold® revenue growth of 10-15% at CER1 Pombiliti®+ Opfolda® revenue growth of 50-65% at CER1 Advance ongoing studies in Fabry, Pompe and FSGS Deliver positive GAAP net income during H2 2025 20 1 CER: Constant E

  21. Slide 21: A Rare Company

    A Rare Company A unique story in biotech with significant revenue growth and profitability Surpassing $1B in Total Sales Double-digit in 2028 Leverageable Revenue Rare Disease Growth Infrastructure Two Approved Self- Therapies Sustainable Company and One Late Stage Growing Free Phase 3 Program Cash

  22. Slide 22: Appendix

    Amicus Therapeutics Appendix

  23. Slide 23: Reconciliation of Non-GAAP Financial Measures

    Reconciliation of Non-GAAP Financial Measures 23

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures (Cont'd)

    Reconciliation of Non-GAAP Financial Measures (Cont’d) 24

  25. Slide 25: Exchange Rates

    Exchange Rates Currency Average Rates FX Rates Q2 2024 Q2 2025 Variance USD/EUR 1.076 1.135 5.4% USD/GBP 1.262 1.336 5.9% USD/JPY 0.006 0.007 7.9% 25

  26. Slide 26: Rare Disease Pipeline

    Rare Disease Pipeline INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FA B R Y D I S E A S E Galafold® (migalastat) Fabry Genetic Medicines POMPE DISEASE Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Pompe Genetic Medicines RARE KIDNEY DISEASE DMX-200 in Foca

Amicus Therapeutics — Q2 2025 Earnings Presentation on 6ix